Actos (pioglitazone) reduces the risk of heart attack and stroke in some patients with type 2 diabetes

October 2005

New evidence shows that Actos (pioglitazone) reduces the risk of heart attack and stroke in some patients with type 2 diabetes.

We know that improving glycemic control reduces the risk of MICROvascular complications...retinopathy, nephropathy, neuropathy.

But there are questions about whether improving glycemic control reduces MACROvascular complications...heart attack and stroke.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

12 issues every year — what you need to know and do, right now
Quick, practical reference charts and tools
Comprehensive CE library to meet license renewal and state requirements
Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote